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Introduction 
A few years after the introduction of aspirin (acetylsalicylic 
acid, ASA) for the treatment of fever and inflammatory 
disorders in 1899, severe intolerance reactions were 
described among subjects taking therapeutic doses of aspi- 
rin (l-3). The exact mechanism by which the intolerance 
reaction is triggered remains elusive, as why only certain 
individuals exhibit this particular sensitivity. However, 
the patients are intolerant to all non-steroidal anti- 
inflammatory drugs (NSAIDs) inhibiting the cyclo- 
oxygenase enzyme which catalyses the formation of 
prostaglandins and thromboxane (4). Furthermore, asth- 
matic subjects with rhinitis and recurrent nasal polyposis 
are particularly prone to develop aspirin intolerance, pro- 
viding the clinical triad of nasal polyposis, asthma and 
aspirin intolerance (5,6). A typical intolerance reaction 
occurs within 30 min2 h after intake of the drug. Severe, 
persistent airway obstruction, nasal congestion, ocular 
injection, flush, heat rash, perspiration and occasionally 
gastrointestinal symptoms may occur in isolation or in 
combination. The reaction may progress into shock and 
respiratory arrest. 
There is no in vitro test which specifically can diagnose 
aspirin intolerance. Therefore, in the case of an ambiguous 
history the diagnosis requires provocation with ASA or 
another NSAID. Nasal provocations with lysine-aspirin (a 
more soluble derivative of aspirin) have rather low sensitiv- 
ity (7,8) but would be of interest to develop further as an 
initial screening test. Oral provocation with aspirin has 
been used for many years to diagnose aspirin-induced 
asthma (9), but this procedure is time consuming, always 
associated with the risk of provoking severe bronchial 
and/or systemic reactions and clearly unsuitable for routine 
clinical practice. 
Bronchial provocation with lysine-aspirin was introduced 
by Bianco and coworkers in 1977 (10) and has been 
documented to be a useful diagnostic means in aspirin- 
induced asthma (11-13). In a prospective comparative 
study the aspirin bronchoprovocation was found to be as 
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sensitive as the oral provocation with respect to detection of 
airway obstruction (12). Table 1 summarizes the main 
findings of the study, i.e. the bronchoprovocation was 
easier to control and produced no systemic reactions. 
In addition, no unspecific airway responses to inhaled 
lysine-ASA were observed in an aspirin-tolerant control 
group. 
The communication will describe a standardized protocol 
for aspirin inhalation challenge now being used in several 
European centres which participate in AIANE (European 
Network of Aspirin Induced Asthma). The repeatability 
and application of the inhalation challenge will also be 
presented. 
Protocol for Bronchial Challenge with 
ASA 
ADMINISTRATION 
Lysine-aspirin (ASA, acetylsalicylic acid) is administered by 
a dosimeter-controlled jet nebulizer (Spira Elektro 2, 
Respiratory Care Centre, Hameenlinna, Finland). As 
indicated in Table 2, by the use of two or sometimes three 
different solutions of lysine-ASA and by variations in the 
number of tidal breaths, stepwise increments in the dose of 
inhaled lysine-ASA will be achieved to produce the desired 
protocol for the cumulative challenge. Nebulizer settings 
are shown in Table 3. 
LYSINE-ASPIRIN SOLUTIONS 
Crystalline lysine-ASA (Aspisol@, Horby Bayer AG, 
Germany; Flectadol@, Maggioni-Winthrop, Italy) is 
provided in vials containing 1 g (Aspisol@) or 2 g 
(Flectadol@) of lysine-ASA. This corresponds to 500 and 
1000 mg of ASA respectively. 
The lysine-ASA solutions are prepared fresh, just before 
the start of the bronchoprovocation, by dissolving the 
crystalline lysine-ASA in saline (0.9% sodium chloride). 
Crystalline lysine-ASA is very stable and may be kept at 
room temperature for prolonged periods, whereas solutions 
of lysine-ASA are stable only for 2 h in the refrigerator. 
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TABLE 1. Challenge with aspirin by different routes in aspirin-sensitive asthmatics 
Provocation method 
Summary of findings Oral Bronchial 
Bronchoconstriction 
(2 20% fall in FEV,) 
Maximal fall in FEV, 
(mean f SD) 
Drugs required for reversal 
Duration of test session 
Extrapulmonary reactions 
9/10 
- 38 f 16% 
Bronchodilators and steroids systemically 
>8h 
6/10 
9/10 
- 29% f 6% 
Inhaled P-agonists 
<4h 
o/10 
TABLE 2. Protocol for dosing of lysine-aspirin 
Aspirin 
concentration 
(M) 
No. 
of 
breaths 
Dose 
Olmol) 
Cumulative 
dose 
Olmol) In 
Increase 
in 
In units 
0.1 
0.1 
0.1 
1.0 
1.0 
1.0 
2.0 
2.0 
1 1 1 0 0 
2 2 3 1.1 +1 
4 4 7 1.9 +1 
1 10 17 2.8 +1 
4 40 57 4.0 +1 
9 90 147 5.0 +1 
13 260 401 6.0 +1 
35 700 1107 7.0 +1 
Preparation of Solutions 
For most challenges in sensitive subjects, it is sufficient to 
make two solutions of lysine-ASA (0.1 and 1 M). The 
two solutions are made from the content of one vial of 
crystalline lysine-ASA. 
For example, using Aspisol@ the 1 M stock solution 
(360 mg ml ~ ’ of lysine-ASA= 180 mg ml ~ ’ of ASA) is 
made by dissolving one vial of crystalline lysine-ASA 
(1 g lysine-ASA=0.5 g ASA) in 2.8 ml saline. 
A ten-fold dilution of the 1 M stock solution is produced 
by taking 0.5 ml of the 1 M stock and adding this to 4.5 ml 
of saline. This gives a 0.1 M solution (36 mg ml- ’ of 
lysine-ASA= 18 mg ml ~ ’ of ASA). Please make sure that 
the 1.0 M stock solution is dissolved (has cleared up) before 
performing the dilution. 
TABLE 3. Nebulizer settings 
Inspiratory flow rate 
Starting volume 
Tidal volume 
Duration of nebulization 
output 
0.51s-’ 
50 ml 
0.550.6 1 
0.8 s 
10.3 ,~l per breath 
These settings provide an aerosol with 80% of the particles 
being less than 5.8pm and a mass median diameter of 
4.1 pm (14). 
In subjects who are less sensitive to aspirin, it may be 
required to prepare also a 2.0 M solution of lysine-ASA. 
This concentrated stock solution is obtained by dissolving 
one vial of lysine-ASA in 1.4 ml of saline (720 mg ml ~ ’ of 
lysine-ASA= mg ml - ’ of ASA). The use of this more 
concentrated solution reduces the number of breaths 
required to produce the two highest doses of lysine-ASA in 
the protocol (Table 2). 
The solutions are kept in the refrigerator during the 
provocation but must be brought to room temperature 
before each administration. A minimum of 1 ml of solution 
is required in this particular nebulizer. 
CHALLENGE PROCEDURE 
Determination of Baseline FEV, 
The baseline FEV, will first be measured as the best of three 
efforts. If the baseline FEV, is above 60% of predicted, the 
test will normally be performed unless clinical judgement 
advises against (Fig. 1). 
Determination of Diluenf Response and Post-d&tent 
Baseline 
FEV, and PEFR are recorded 10 and 20 min after in- 
halation of diluent (seven breaths of saline). If stable, this 
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FIG. 1. Time course of bronchoprovocation with approxi- 
mately half log,, increments of lysine-aspirin in an 
aspirin-sensitive asthmatic subject (11 March 1991; sub- 
ject, 43 year old woman). 
value will be used as post-diluent baseline. If a significant 
response to the diluent occurs (more than 10% deviation 
from the pre-diluent value), the diluent inhalation may be 
repeated. If there remains a significant diluent response, the 
challenge should not be performed this day. In the absence 
of a diluent response, the provocation will continue and the 
20 min post-diluent baseline will be used to calculate the 
percentage drop in FEV, during the challenge. 
Inhafation of Lysine-aspirin 
The lysine-ASA solution is inhaled every 30 min. Approxi- 
mately logarithmic dose increments are administered 
according to Table 2. FEV, and PEFR are obtained at 10, 
20 and 30 min after each dose. The provocation is stopped 
when FEV, has fallen 20% or more from the post-diluent 
baseline or the maximum dose of ASA has been reached 
(approximately 1100 pmol cumulative dose). 
If the decrease in FEV, at 30 min after an inhaled dose is 
between 15% and 20%, indicating the development of a 
positive reaction, it is advised to wait another 10 min before 
a further dose increment. If the drop in FEV, remains 
between 15% and 20%, a decision must be made by the 
responsible physician as to whether or not the next dose in 
the protocol should be given. In subjects with a steep 
dose-response relation for lysine-ASA and/or a high degree 
of histamine responsiveness, it is for safety purposes recom- 
mended to repeat the previous dose once more rather than 
giving the next dose in the protocol. This provides a more 
gentle updosing. In this context it is noteworthy that 
bronchial absorption of inhaled aspirin does occur, yielding 
measurable plasma levels of ASA and its main metabolite 
salicylic acid after aspirin inhalation challenges (15). It is 
therefore likely that with higher doses of inhaled aspirin 
extrapulmonary symptoms may occur. 
After a positive reaction FEV, and PEFR are followed 
every 15 min until FEV, has returned to within 10% of the 
post-diluent baseline. The patient should always be 
observed for at least 1 h after the termination of the 
provocation. Although typical late reactions have not been 
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FIG. 2. Dose-response relations for lysine-aspirin in an 
aspirin-sensitive asthmatic subject (subject No. 63) under- 
going aspirin bronchoprovocations at three occasions; 
without pre-treatment (0) and after double-blind pre- 
treatment with placebo (A) and with a leukotriene antag- 
onist (A). 
documented following aspirin challenge (11 ,I 3), the chal- 
lenged subject should be advised to record PEFR in the 
case of airway symptoms. Before leaving the clinic, it 
should therefore be written on the PEFR chart at which 
predefined level of drop in PEFR that the subject should 
use rescue medication and/or contact the hospital. 
Dose-response relations for ASA are constructed and 
used for the calculation of PD,,. The lowest FEV, measure- 
ment at 10, 20 or 30 min after each dose is plotted against 
the cumulative dose of ASA; the PD,, value is derived from 
linear interpolation between the two last doses (Fig. 2). 
Repeatability 
The repeatability of the challenge is very good for the 
methodology described above. Thus, on the basis of the 
results of two challenges separated by lo-75 days, the 95% 
confidence interval for the PD,, value was between 0.6 and 
1.8 times the observed value (Fig. 3). 
For research purposes, and in particular in studies 
involving pharmacological manipulations of the response, 
the repeatability of the provocation is crucial. As an 
example is illustrated (Fig. 2) the dose-response curves to 
inhaled aspirin in a sensitive subject participating in a study 
on the influence of the leukotriene antagonist MK-0679 on 
aspirin-induced airway obstruction (17). The subjects 
underwent three bronchoprovocations. A pre-study provo- 
cation established the current aspirin PD,,; thereafter two 
provocations were carried out after double-blind, rand- 
omized, cross-over treatment with the leukotriene antagon- 
ist and placebo. Ideally, as in this case, the dose-response 
curves at pre-study and on the placebo day slope almost 
identically, whereas a marked shift is achieved on the active 
drug treated day. Also, for the whole group the geometric 
mean values for aspirin PD,, were very similar at pre-study 
and after placebo treatment, while the leukotriene antagon- 
ist caused a highly significant (WO.001) increase of the 
aspirin PD,,, with a median shift being 4.4-fold (Fig. 4). 
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FIG. 3. Repeatability of lysine-aspirin bronchoprovoca- 
tion in aspirin-sensitive asthmatic subjects. The difference 
in log PD,, between the two challenge sessions is plotted 
against their mean (16). 
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FIG. 4. Group geometric mean f SE for aspirin after treat- 
ment with placebo (a) and the leukotriene receptor antag- 
onist MK-0679 (w) and, for comparison, at the pre-study 
challenge (0). *** indicates significant difference between 
placebo and MK-0679 (P=O.OOl; Wilcoxon paired). There 
was no difference in mean PD,, values between placebo 
and pre-study sessions. 
In this context it should be noted that after a positive 
provocation response to inhaled (or oral) aspirin, a state 
of refractoriness to further doses of aspirin or other 
NSAIDs follows (10,18). The refractory period lasts 
between 2 and 5 days. As a corollary, desensitization as well 
as cross-desensitization may be retained provided that 
aspirin is ingested with a maximum interval of 48 h. 
Complete sensitivity to aspirin and other NSAIDs reap- 
pears about 7 days after the last exposure to these drugs 
(18). Therefore, repeated challenges for diagnosis or 
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research purposes should be separated by at least 1 week. 
Another pitfall which may produce false-negative 
aspirin provocations is indicated by observations that 
high doses of glucocorticosteroids may mask aspirin 
intolerance (19). 
Patterns of Bronchial Response 
In another method of inhalation challenge lysine-aspirin is 
administered by a dosimeter [MB,, MeFAR Elettro- 
Medicali, Brescia, Italy (13)]. The dosimeter’s characteris- 
tics are as follows: particle size, 0.555,~rn; air driving 
pressure, 1.65 kgf cm - *; air flow rate, 7.0-7.5 1 mini ‘; 
nebulization time, 0.8 + 0.2 s; output, 5 * 0.2 ml per puff. 
Lysine acetylsalicylate (Flectadol 1000, Maggioni - 
Winthrop S.pA., Italy), as a powder containing 1800 mg of 
lysine-ASA (i.e. 1000 mg of aspirin) and 200 mg of glycine, 
is dissolved in 5 ml of distilled water to obtain a 20% 
solution. Then, 3 mg of this solution are placed in the 
nebulization chamber. Delivery time is set to produce the 
nebulization of 5 mg of solution, i.e. 1 mg of lysine-ASA for 
each puff. After the initial administration of diluent control 
solution, doubling increasing concentrations of lysine-ASA 
(from 1 to 64 mg as cumulative dose) are given at 30 min 
intervals. 
The patient, starting at functional residual capacity, 
slowly and completely inhales the delivered dose breathing 
at inspiratory capacity via a mouthpiece inserted above the 
tongue and wearing a nose clip. The breath is then held for 
5 s before slow exhalation. 
FEV, is recorded at 10, 20, and 30 min after each dose 
step. Inhalations progress until either a fall 220% from 
baseline occurs or the top dose is reached. Results are 
expressed as PD,, lysine-ASA, i.e. the dose of lysine-ASA 
in mg provoking a fall of 220% in FEV, from baseline 
(intended as the post-diluent registered value). Patients 
should be monitored up to 8 h thereafter for the possible 
onset of late reactions. 
Airway response to the challenge appears within 
20-30 min and reaches its maximum at about 40 min after 
the provocation dose. The recovery time from induced 
bronchoconstriction (return to within 10% of post-diluent 
baseline) is variable, ranging from 2-3 to 6 h or longer 
(Fig. 5). This typical pattern led to the definition of ‘early 
prolonged reaction’ (13). Late reactions, however, have 
not been observed, thus confirming the results of other 
investigations (11,12). 
Airway Responsiveness in ASA-sensitive 
Subjects 
Subjects with ASA sensitivity do not constitute a homo- 
geneous population. Clinically, there are at least two 
well-defined subpopulations of individuals: one with 
cutaneous manifestations (urticaria and/or angioedema), 
the other with respiratory manifestations (bronchial 
asthma, rhinitis) (20). Combined respiratory and cutaneous 
manifestations are very rare in patients with asthma. 
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FIG. 5. Pattern of bronchial response showing an ‘early 
prolonged reaction’: PD,, at 20 min; maximum FEV, 
decrease at 1 h; complete recovery at above 6 h. 
Bronchial hyperresponsiveness (BHR) has been investi- 
gated in different groups of aspirin-sensitive subjects 
(21,22). 
BHR was determined by methacholine test (MT) 
performed by the MB, dosimeter (Mefar, Italy) whose 
characteristics have been previously described. The result of 
the test is expressed as provocative dose (PD,, MT), which 
is the dose (in mg) of methacholine provoking a 20% fall 
from baseline FEV,. A PD,, > 16OOpg is regarded as 
normal responsiveness. The reproducibility of the test is 
a & 1.66-fold difference in PD,, and a confidence interval 
(CI) of 95%. 
Baseline BHR was studied in two groups of asthmatics: 
group A, including 23 ASA-sensitive asthmatics, and group 
B, including 23 non-ASA-sensitive asthmatics. 
BH was variable but within the range observed in asth- 
matic patients, with no significant differences in two groups, 
except for three ASA-sensitive asthmatics who showed 
normal responsiveness (Fig. 6). These subjects suffered 
from episodic asthma and were symptom free since several 
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FIG. 7. Relationship between PD,, to methacholine and 
PD,, to lysine-ASA in a group of 25 ASA-sensitive asth- 
matics: no correlation appeared between airway respon- 
siveness to methacholine and to lysine-ASA 
(J=4585x+232.342; ?=0.05). 
months before the test. In another group of 25 ASA- 
sensitive asthmatics, the relationship between PD,, MT and 
PD,, lysine-ASA was examined. There was no correlation 
between airway responsiveness to methacholine and lysine- 
aspirin (Fig. 7). This finding differentiates the lysine-ASA 
inhalation challenge from those with antigens, where a 
correlation between PD,, MT and PD,, allergen has been 
shown. 
Changes in airway responsiveness to methacholine after 
challenge with lysine-ASA were examined in a group of 18 
patients. They performed on three consecutive days MT, 
lysine-ASA challenge and again MT. In five patients 
(27.7%) a significant increase in PD,, was observed after 
lysine-ASA challenge. In five patients a significant decrease 
in PD,, was recorded instead (Fig. 8). Lastly, BHR was 
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FIG. 6. Bronchial hyper-responsiveness in (a) 23 ASA-sensitive asthmatics and (b) 23 non-ASA-sensitive asthmatics: no 
significant differences between the two groups except for three ASA-sensitive asthmatics who resulted normoresponsive. 
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FIG. 8. Changes in airway responsiveness after lysine- 
ASA challenge: in five out of 18 patients (27.7%) a signifl- 
cant decrease in PD,, MT was observed, while in one 
patient PD,, MT was increased. 
evaluated in a group of ASA-sensitive patients with urti- 
caria and/or angioedema without respiratory symptoms. 
All patients showed normal BHR, a negative lysine-ASA 
inhalation challenge and a positive oral lysine-ASA test. No 
changes in BH were observed after both inhaled and oral 
challenge, even in the presence of a positive oral challenge. 
In conclusion, inhalation challenge with lysine-aspirin, 
performed with cumulative breath units (11) or with a 
dosimeter, allows us to construct a concentration or dose- 
response curve and to obtain a quantitative estimation of 
airway responsiveness to the drug. Because of its many 
advantages, this method is likely to replace the oral 
challenge for the detection of ASA-induced asthma. 
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